Patent Expirations and Market Impact
Sugammadex (Bridion)
Mechanism of Action: Binding agents Drug class: Gamma-Cyclodextrins; Muscle relaxants Originator: Organon Indications: Neuromuscular blockade Patent expiry: January 2026
Bridion market revenue for eleven years (2015- till Sept, 2025)
Bridion has experienced a consistent increase in market revenue over the past eleven years, highlighting its growing acceptance and widespread use in clinical anesthesia practice. This sustained growth reflects strong physician confidence, expanding global adoption, and the drug’s established role in improving patient outcomes during neuromuscular blockade reversal.
Market revenue of Sugammadex (2015- till Sept, 2025)
Fig 8: Market revenue of Sugammadex
How will the patent expiry of Bridion affect the market?
Bridion (sugammadex) is approaching a major patent milestone in the U.S., with core patent protection set to expire around January 2026, a timeline reinforced by recent court rulings. While certain method-of-use and exclusivity protections for specific patient populations extend into 2027 and 2028, the expiry of the primary patent opens the door for generic competition beginning in 2026. Several international patents have already lapsed, signaling the start of broader market erosion.
In anticipation of U.S. generic entry, multiple manufacturers have secured FDA approvals for generic versions of sugammadex. ASPIRO received approval in June 2023, followed by B. Braun Medical's generic version approval in August 2025, while Hikma Pharmaceuticals has also pursued pre-patent expiry for FDA clearance. Collectively, these developments position 2026 as a pivotal year for Bridion, with increased competition expected to impact its U.S. market dynamics. The cost of a Bridion 100 mg/mL solution varies significantly based on location, supplier, and packaging size (vial size). In the U.S., the wholesale acquisition cost of Bridion per 1 mL single-dose vial ranges from approximately $67 to over $100. Generic sugammadex offers meaningful discounts, typically delivering 30–70% savings versus the brand, though pricing varies by pharmacy, location, and insurance, with U.S. discounted generics generally starting around $70–$80 per mL for smaller doses.
Bridion cost per single-dose vial
Generic cost per single-dose vial